个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE ◇ 统计源期刊 ◇ CSCD-C ◇ 卓越：梯队期刊

作者：
Zhang Jianwei[1] ; Zhu Haibin[2] ; Shen Lin[3] ; Li Jie[1] ; Zhang Xiaoyan[2] ; Bai Chunmei[4] ; Zhou Zhiwei[5] ; Yu Xianrui[6] ; Li Zhiping[7] ; Li Enxiao[8] ; Yuan Xianglin[9] ; Lou Wenhui[10] ; Chi Yihebali[11] ; Xu Nong[12] ; Yin Yongmei[13] ; Bai Yuxian[14] ; Zhang Tao[15] ; Xiu Dianrong[16] ; Chen Jia[17] ; Qin Shukui[18] ; Wang Xiuwen[19] ; Yang Yujie[20] ; Shi Haoyun[20] ; Luo Xian[20] ; Fan Songhua[20] ; Su Weiguo[20] ; Lu Ming[3,*1] ; Xu Jianming[21,*2] ;
机构： [1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China. [2]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiology, Peking University Cancer Hospital & Institute, Beijing 100142, China. [3]State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China. [4]Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China. [5]Department of Gastric Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510062, China. [6]Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China. [7]Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu 332001, China. [8]Department of Medical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. [9]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. [10]Department of General Surgery, Zhongshan Hospital of Fudan University, Shanghai 200032, China. [11]Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. [12]Department of Medical Oncology, the First Affiliated Hospital of Zhejiang University, Hangzhou 310009, China. [13]Department of Medical Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. [14]Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China. [15]Department of Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. [16]Department of General Surgery, Peking University Third Hospital, Beijing 100191, China. [17]Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing 214206, China. [18]Cancer Center of Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing 210016, China. [19]Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan 250012, China. [20]Department of Clinical and Regulatory Affairs, HUTCHMED Limited, Shanghai 200001, China. [21]Department of Gastrointestinal Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing 100071, China.
出处：
DOI： 10.21147/j.issn.1000-9604.2023.05.09
ISSN：

关键词： Neuroendocrine tumors liver metastases computed tomography surufatinib

摘要：
Currently, pre-treatment prediction of patients with pancreatic neuroendocrine tumors with liver metastases (PNELM) receiving surufatinib treatment was unsatisfying. Our objective was to examine the association between radiological characteristics and efficacy/prognosis.We enrolled patients with liver metastases in the phase III, SANET-p trial (NCT02589821) and obtained contrast-enhanced computed tomography (CECT) images. Qualitative and quantitative parameters including hepatic tumor margins, lesion volumes, enhancement pattern, localization types, and enhancement ratios were evaluated. The progression-free survival (PFS) and hazard ratio (HR) were calculated using Cox's proportional hazard model. Efficacy was analyzed by logistic-regression models.Among 152 patients who had baseline CECT assessments and were included in this analysis, the surufatinib group showed statistically superior efficacy in terms of median PFS compared to placebo across various qualitative and quantitative parameters. In the multivariable analysis of patients receiving surufatinib (N=100), those with higher arterial phase standardized enhancement ratio-peri-lesion (ASER-peri) exhibited longer PFS [HR=0.039; 95% confidence interval (95% CI): 0.003-0.483; P=0.012]. Furthermore, patients with a high enhancement pattern experienced an improvement in the objective response ratio [31.3% vs. 14.7%, odds ratio (OR)=3.488; 95% CI: 1.024-11.875; P=0.046], and well-defined tumor margins were associated with a higher disease control rate (DCR) (89.3% vs. 68.2%, OR=4.535; 95% CI: 1.285-16.011; P=0.019) compared to poorly-defined margins.These pre-treatment radiological features, namely high ASER-peri, high enhancement pattern, and well-defined tumor margins, have the potential to serve as predictive markers of efficacy in patients with PNELM receiving surufatinib.Copyright ©2023 Chinese Journal of Cancer Research. All rights reserved.

语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学
最新[2023]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
共同第一作者：
通讯作者：
通讯机构： [3]State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China. [21]Department of Gastrointestinal Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing 100071, China. [*1]State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China. [*2]Department of Gastrointestinal Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing 100071, China
推荐引用方式(GB/T 7714)：
Zhang Jianwei,Zhu Haibin,Shen Lin,et al.Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib[J].CHINESE JOURNAL OF CANCER RESEARCH.2023,35(5):526-+.doi:10.21147/j.issn.1000-9604.2023.05.09.
APA：
Zhang Jianwei,Zhu Haibin,Shen Lin,Li Jie,Zhang Xiaoyan...&Xu Jianming.(2023).Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib.CHINESE JOURNAL OF CANCER RESEARCH,35,(5)
MLA：
Zhang Jianwei,et al."Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib".CHINESE JOURNAL OF CANCER RESEARCH 35..5(2023):526-+

相关文献

[1]Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies. [2]Computed Tomography Number Changes Observed During Computed Tomography-Guided Radiation Therapy for Head and Neck Cancer [3]Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial [4]A Comprehensive Review on Neuroendocrine Neoplasms: Presentation, Pathophysiology and Management [5]Use of ¹¹C-Choline positron emission tomography/computed tomography to investigate the mechanism of choline metabolism in lung cancer. [6]Predictive value of pretreatment positron emission tomography/computed tomography in patients with newly diagnosed extranodal natural killer/T-cell lymphoma [7]Factors That Improve Chest Computed Tomography-Defined Sarcopenia Prognosis in Advanced Non-Small Cell Lung Cancer. [8]Clinicopathological and radiological significance of the collateral vessels of renal cell carcinoma on preoperative computed tomography. [9]Surgery management for sporadic small (≤2 cm), non-functioning pancreatic neuroendocrine tumors: a consensus statement by the Chinese Study Group for Neuroendocrine Tumors (CSNET). [10]Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep).

资源点击量：43377 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号